FTAI Aviation Ltd vs TransMedics Group Inc — how do they compare? FTAI Aviation Ltd trades at $200.52 (market cap $21.93B), while TransMedics Group Inc trades at $75.96 (market cap $2.61B). The key difference: FTAI Aviation Ltd is far larger — about 8.4× TransMedics Group Inc's market cap, and FTAI Aviation Ltd pays a 0.7% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| FTAI | TMDX | |
|---|---|---|
Market Cap | $21.93B | $2.61B |
Sector | Industrials | Technology |
52-Week High | $310.04 | $150.42 |
52-Week Low | $109.92 | $61.99 |
Enterprise Value | $24.97B | $3.01B |
Dividend Yield | 0.7% | — |
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation Ltd. (FTAI) trades at $199.72, down 3.15% on the day, with technical indicators signaling a bearish trend. The company reported strong revenue growth to $2.51B in 2025 and a net income margin near 19%, but has missed earnings expectations for three consecutive quarters. Recent strategic moves include a collaboration for Boeing 737-800 freighters and a major credit facility expansion to over $2 billion, highlighting its focus on aerospace services and the emerging data center power segment.
The outlook is mixed. Strong analyst consensus (18 Buy ratings) and robust profitability metrics like a 226.91% ROE support a bullish long-term view, driven by aerospace growth and data center innovation. However, near-term risks include consistent earnings misses, a high P/E ratio of 42.59, and negative operating cash flow, which could pressure the stock if execution falters or macro conditions worsen.
TransMedics (TMDX) trades at $76.89, up 3.08% today, with a bullish technical signal from moving averages. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in PAD Aviation aims to expand its organ transplant logistics network in Europe, enhancing its competitive position.
The outlook remains positive with a consensus price target of $108.71, representing 41% upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion investments and competitive threats. Investors should weigh strong long-term growth initiatives against near-term execution challenges.
Trailing returns across standard periods
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →